Co-Chair
Peter R. Farina, Ph.D., chief executive officer, Developing World Cures, Inc.
Co-Chair
David W. Keiser, director, CureFAKtor LLC
President & CEO
Paul R. Pescatello, J.D., Ph.D., president & CEO, CURE
Secretary
Bruce D. Alexander, vice president & director of New Haven and state affairs, Yale University
Treasurer
Michelle Bowman, partner, PricewaterhouseCoopers LLP
Executive Committee Members
Bruce D. Alexander, vice president & director of New Haven and state affairs, Yale University
Jame G. Baxter, Pharm.D., Ph.D., senior vice president, development, Boehringer Ingelheim Pharmaceuticals, Inc.
Derek Chalmers , Ph.D., president & CEO, Cara Therapeutics, Inc.
Peter R. Farina, Ph.D., chief executive officer, Developing World Cures, Inc.
David W. Keiser, director, CureFAKtor LLC
Frank J. Marco, J.D., partner, Wiggin and Dana LLP
Harry H. Penner, Jr., president & CEO, New Haven Pharmaceuticals, Inc.
Paul R. Pescatello, J.D., Ph.D., president & CEO, CURE
Kevin Rakin, president, Advanced BioHealing
David I. Scheer, president, Scheer and Company
Board of Directors
Daniel D. Adams, executive chairman, Protein Sciences Corporation
Bruce D. Alexander, vice president & director of New Haven and state affairs, Yale University
Philip E. Austin, president, University of Connecticut
James G. Baxter, Pharm.D., Ph.D., senior vice president, development, Boehringer Ingelheim Pharmaceuticals, Inc.
Laurine M. Bow, vice president for research and director, transplant immunology, Hartford Hospital.
Michelle Bowman, partner, PricewaterhouseCoopers LLP
Derek Chalmers, Ph.D., president & CEO, Cara Therapeutics, Inc
Thomas Dubin, senior vice president and chief legal officer, Alexion Pharmaceuticals, Inc.
Peter R. Farina, Ph.D., chief executive officer, Developing World Cures, Inc.
Judith B. Greiman, president, Connecticut Conference of Independent Colleges
Joseph P. Hammang, Ph.D., senior director, worldwide science policy, Pfizer, Inc.
James W. Heins, senior director, public affairs, Purdue Pharma
Peter R. Hicks, vice president, emerging growth and technologies, Webster Bank
David W. Keiser, director, CureFAKtor LLC
Michael D. Kishbauch, president and CEO, Achillion Pharmaceuticals, Inc.
Hollis D. Kleinert, Ph.D., president, Kleinert Scientific/Commercial Consultations
Mark Leuchtenberger, president & CEO, Rib-X Pharmaceuticals, Inc.
David M. Mack, J.D., partner, Shipman & Goodwin LLP
Frank J. Marco, J.D., partner, Wiggin and Dana LLP
Anthony Marone, vice president, client & external relations, The United Illuminating Company
Juergen Martens , Ph.D., corporate vice president of technical operations and chief technical officer, MannKind Corporation
Christopher K. McLeod, president and CEO, 454 Life Sciences
Sandra S. Oliver, vice president of public policy & state government affairs, Bayer HealthCare
Harry H. Penner, Jr., president & CEO, New Haven Pharmaceuticals, Inc.
Paul R. Pescatello, J.D., Ph.D., president & CEO, CURE
Kevin Rakin, president, Advanced BioHealing
Jonathan M. Rothberg, Ph.D., CEO and chairman, Ion Torrent
Seth A. Rudnick, M.D., general partner, Canaan Partners
David I. Scheer, president, Scheer and Company
Michael Schmertzler, CEO & president, Kolltan Pharmaceuticals, Inc.